DE60327068D1 - Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass - Google Patents

Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass

Info

Publication number
DE60327068D1
DE60327068D1 DE60327068T DE60327068T DE60327068D1 DE 60327068 D1 DE60327068 D1 DE 60327068D1 DE 60327068 T DE60327068 T DE 60327068T DE 60327068 T DE60327068 T DE 60327068T DE 60327068 D1 DE60327068 D1 DE 60327068D1
Authority
DE
Germany
Prior art keywords
xenon
deficites
neurological
control
bypass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327068T
Other languages
English (en)
Inventor
N P Franks
M Maze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protexeon Ltd
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60327068(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of DE60327068D1 publication Critical patent/DE60327068D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Credit Cards Or The Like (AREA)
DE60327068T 2002-05-01 2003-05-01 Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass Expired - Lifetime DE60327068D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0209998.4A GB0209998D0 (en) 2002-05-01 2002-05-01 Use
PCT/GB2003/001867 WO2003092707A1 (en) 2002-05-01 2003-05-01 Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass

Publications (1)

Publication Number Publication Date
DE60327068D1 true DE60327068D1 (de) 2009-05-20

Family

ID=9935900

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327068T Expired - Lifetime DE60327068D1 (de) 2002-05-01 2003-05-01 Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass

Country Status (12)

Country Link
US (1) US7442383B2 (de)
EP (1) EP1499329B2 (de)
JP (2) JP4939751B2 (de)
AT (1) ATE427750T1 (de)
AU (1) AU2003227896B2 (de)
BR (1) BR0309624A (de)
CA (1) CA2483097C (de)
DE (1) DE60327068D1 (de)
ES (1) ES2323582T5 (de)
GB (1) GB0209998D0 (de)
MX (1) MXPA04010855A (de)
WO (1) WO2003092707A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
AU2004283448B2 (en) * 2003-10-21 2009-02-19 Imperial Innovations Limited Use of xenon for the prevention of programmed cell death
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
EP1980261A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung von Helium mit Sauerstoff zur Bereitstellung von Neuroprotektion
EP1980260A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
AU2014233018A1 (en) * 2013-03-15 2015-10-01 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
CA2968722C (en) * 2016-06-03 2022-06-07 Lakehead University In vivo detection of a xenon-binding cage molecule
US20220184293A1 (en) * 2019-03-25 2022-06-16 Mallinckrodt Pharmaceuticals Ireland Limited Gas delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6589621B1 (en) * 1998-07-01 2003-07-08 Dow Global Technologies Inc. Thermally stable polyetheramines
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use

Also Published As

Publication number Publication date
JP2005530750A (ja) 2005-10-13
JP4939751B2 (ja) 2012-05-30
WO2003092707A1 (en) 2003-11-13
JP2011102290A (ja) 2011-05-26
CA2483097C (en) 2011-07-12
EP1499329A1 (de) 2005-01-26
EP1499329B1 (de) 2009-04-08
AU2003227896B2 (en) 2008-08-14
ES2323582T3 (es) 2009-07-21
ATE427750T1 (de) 2009-04-15
US20050238726A1 (en) 2005-10-27
US7442383B2 (en) 2008-10-28
CA2483097A1 (en) 2003-11-13
MXPA04010855A (es) 2005-02-14
ES2323582T5 (es) 2012-08-22
EP1499329B2 (de) 2012-05-23
GB0209998D0 (en) 2002-06-12
BR0309624A (pt) 2005-02-09
AU2003227896A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
IL250826B (en) Methods for treating bone cancer pain by administering a growth factor antagonist
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
NO20054371L (no) Somatostatin-dopamin kimaere analoger
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
ATE521353T1 (de) Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
DE60327068D1 (de) Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE395826T1 (de) Verwendung von 3-(2,4,6-trimethylphenyl)-4- neopentylcarbonyloxy-5,5-tetramethylen- dihydrofuran-2-on zur bekämpfung von psylliden
NO20071378L (no) Tiazolo-naftylsyrer.
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
DE602004023922D1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
DE50002119D1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
MY140194A (en) Novel fusidic acid derivatives
ATE333274T1 (de) Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
DE602004012152D1 (de) Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen
ATE355063T1 (de) Methode zur behandlung von niereninsuffizienz
WO2006073981A3 (en) Regulation of microphage migration inhibitory factor (mif) activity
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
DE59911733D1 (de) Verwendung von adenoassoziierten viren zur senkung der radio- oder chemotherapieinduzierten resistenz bei krebspatienten
DE50011129D1 (de) Verwendung von parvoviren zur verbesserung des allgemeinzustandes bei tumorpatienten oder patienten mit chronischen oder konsumierenden erkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent